TYME - Tyme stock granted U.S. patent claims for using TYME-19 to treat COVID-19 infections

Tyme Technologies (TYME) rallied 89% in premarket trade after it received notification that the U.S. Patent and Trademark Office granted additional patent claims related to the company's metabolomic technology platform which is directed to methods for treating COVID-19.Unlike immune therapies that depend upon the structure of the external virus coat of COVID-19 where the therapy directs its attack, the company believes TYME-19 is agnostic to this structure and any mutations to the viral coat. Like other TYME agents, TYME-19 affects cellular metabolism.The company intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19.Earlier in August 2020, the company initiated to test TYME-19 as COVID-19 treatment.

For further details see:

Tyme stock granted U.S. patent claims for using TYME-19 to treat COVID-19 infections